ArticleNeurosurgical review2022
Mid-term follow-up surgical results in 284 cases of clival chordomas: the risk factors for outcome and tumor recurrence.
Article in Neurosurgical review, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- Skull base chordomas - emphasis on surgical strategy and recurrence-free survival.Medicine and pharmacy reports · 2025Article
- Endoscopic Endonasal Resection of Clival Chordomas.Advances and technical standards in neurosurgery · 2025Review
- Extracellular Vesicles from a Novel Chordoma Cell Line, ARF-8, Promote Tumorigenic Microenvironmental Changes When Incubated with the Parental Cells and with Human Osteoblasts.International journal of molecular sciences · 2024Article
- Proteogenomic characterization of skull-base chordoma.Nature communications · 2024Article
- Clival chordomas and chondrosarcomas in Denmark-Outcomes in 33 patients following the national centralization of treatment in 2010.Acta neurochirurgica · 2024Article
- Review
- Surgical management of skull base chordomas and chondrosarcomas: insights from a national cohort study.BMJ oncology · 2024Article
- Combined microscopic transoral and endoscopic endonasal approach for a clival chordoma: A case report and literature review.Surgical neurology international · 2024Article
- Article
- Lynch syndrome-associated chordoma with high tumor mutational burden and significant response to immune checkpoint inhibitors.Brain tumor pathology · 2023Article
- Case report: Side-firing intraoperative ultrasound guided endoscopic endonasal resection of a clival chordoma.Frontiers in oncology · 2023Article
- The prognostic significance of different degrees of resection of skull base chordoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Article
- A correlation analysis of sacrococcygeal chordoma imaging and clinical characteristics with the prognostic factors.Frontiers in oncology · 2022Article
- Factors associated with artificial airway retention after skull base chordoma resection: A retrospective cohort study.Frontiers in neurology · 2022Article
- Intraoperative Magnetic Resonance Imaging Assisted Endoscopic Endonasal Resection of Clival Chordomas.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSkull base chordoma (SBC) is rare and one of the most challenging diseases to treat. We aimed to assess the optimal timing of adjuvant radiation therapy (RT) and to evaluate the factors that influence resection and long-term outcomes.
methodsIn total, 284 patients with 382 surgeries were enrolled in this retrospective study. Postsurgically, 64 patients underwent RT before recurrence (pre-recurrence RT), and 47 patients underwent RT after recurrence. During the first attempt to achieve gross-total resection (GTR), when the entire tumor was resected, 268 patients were treated with an endoscopic midline approach, and 16 patients were treated with microscopic lateral approaches. Factors associated with the success of GTR were identified using χ
resultsIn total, 74.6% of tumors were marginally resected [GTR (40.1%), near-total resection (34.5%)]. History of surgery, large tumor volumes, and tumor locations in the lower clivus were associated with a lower GTR rate. The mean follow-up period was 43.9 months. At the last follow-up, 181 (63.7%) patients were alive. RT history, histologic subtype (dedifferentiated and sarcomatoid), non-GTR, no postsurgical RT, and the presence of metastasis were associated with poorer CSS. Patients with pre-recurrence RT had the longest PFS and CSS, while patients without postsurgical RT had the worst outcome.
conclusionGTR is the goal of initial surgical treatment. Pre-recurrence RT would improve outcome regardless of GTR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.